What it is
Carnosine is a dipeptide: two building blocks joined by one peptide bond. The first is beta-alanine, the second L-histidine. PubChem (CID 439224) gives its formula as C9H14N4O3 and its weight as 226.23.
Beta-alanine is the unusual part. Its amino group sits one carbon further along than in ordinary alanine, and it is not one of the 20 amino acids cells use to build proteins.
Anserine, which this entry also covers, is carnosine with a single methyl group on histidine's ring (PubChem CID 112072, weight 240.26). Both occur in meat and fish.
Where it is found and what it does
A 2026 trial report describes carnosine as abundant in highly metabolic tissues such as skeletal muscle and brain, where it is thought to buffer acid inside working cells (O'Toole 2026, PMID 42308284). That buffering role is the basis for its sale as a sports supplement, alongside its building block, beta-alanine.
What happens when it is swallowed
The most useful single study is Harris 2006 (PMID 16554972):
| Finding | Figure |
|---|---|
| Carnosine or anserine in blood after chicken broth | Not detected (traces in urine only) |
| Beta-alanine in blood after the broth | Peak 428 µM, back to baseline by 2 hours |
| Muscle carnosine after 4 weeks of beta-alanine, 3.2 g/day | +42.1% |
| Muscle carnosine after 4 weeks of beta-alanine, 6.4 g/day | +64.2% |
| Muscle carnosine after 4 weeks of L-carnosine (isomolar to 6.4 g beta-alanine) | +65.8% |
So dietary carnosine did not reach blood intact in that study, yet carnosine supplements raised muscle stores about as much as beta-alanine did. The paper's own data fit the reading that the gut and blood break carnosine apart and muscle rebuilds it — a route the abstract does not test directly.
What the human trials show
| Trial | People | Dose, length | Result |
|---|---|---|---|
| Hariharan 2024 (PMID 38172006) | 43, prediabetes or type 2 diabetes | 2 g/day, 14 weeks | Glucose −1.31 mmol/L at 90 min and −1.60 at 120 min of a glucose-tolerance test; insulin unchanged; no change in body composition |
| Saadati 2023 (PMID 38004228), Monash | 49, prediabetes or type 2 diabetes | 2 g/day, 14 weeks | No effect on blood pressure, arterial stiffness, endothelial function, lipids, liver or kidney markers |
| NEAT — endurance (PMID 42308284) | 299 randomised | 2 g/day, 12 weeks | Gains only in subgroups (calf raises under 40; step test in men over 40); none in grip strength |
| NEAT — cognition (PMID 39919936) | 299 randomised, ~231–242 measured | 2 g/day, 12 weeks | Gains in the youngest age stratum only; a post-hoc analysis |
Three limits run through the table. The trials are small. The positive findings in NEAT come from subgroups, which are a reason for a new trial, not a result. And in the glucose trial the supplier provided the carnosine, though the authors state it had no role in the study.
Safety
The trials above report no safety signal at 2 g/day over 12–14 weeks, but none was designed or sized to find one. "No harm reported" in small, short trials is not the same as shown to be safe. Carnosine is sold as a dietary supplement; no FDA-approved drug lists it as an active ingredient (Drugs@FDA, 2026-10-05).
Where it stands
ClinicalTrials.gov returns 53 studies naming carnosine as an intervention (2026-10-05); some test zinc–carnosine (polaprezinc), a different compound studied as a stomach-lining drug. PubMed indexes 3,608 records for carnosine, 159 tagged as randomised controlled trials (2026-10-05).
Related reading
Carnosine is one of the few peptides in this library sold as a food supplement, alongside glutathione, a tripeptide with a similar antioxidant reputation. For how two amino acids become one molecule, see the peptide bond; for the much longer peptides that act as hormones, compare IGF-1.